The upcoming announcement for the 2024 Medicare Part B premiums raises questions of a possible increase due to coverage of a new, expensive Alzheimer’s drug, Leqembi, mirroring the situation in 2022 with a different Alzheimer’s drug, Aduhelm. Although Leqembi is not a cure and is only approved for certain patients, it is the first drug to clinically slow down the disease’s progression.
Six Questions Every CFO Should Ask About AI
The AI wave in healthcare revenue cycle management (RCM) shows no signs of slowing down. Every week, new solutions promise automation, intelligence, and operational efficiency.
